[Update on celiac disease].
The prevalence of Celiac disease in the general population is approximately 1% and remains undiagnosed in a significant proportion of individuals. Its clinical presentation includes the classical malabsorption syndrome, unspecific and extra-intestinal manifestations, and silent celiac disease. The serologic diagnosis has an elevated sensitivity and specificity and, at least in adult population, it must be confirmed by biopsy in every case. Diagnosis in subjects already on gluten free diet includes HLA typing and gluten challenge with posterior serologic and histologic evaluation. The core of the treatment is the gluten free diet, which must be supervised by an expert nutritionist. Monitoring must be performed with serology beginning at 3-6 months, and with histology two years after the diagnosis, unless the clinical response is poor. Poor disease control is associated with complications such as lymphoma and small bowel adenocarcinoma. In the future, it is likely that new pharmacologic therapies will be available for the management of celiac disease.
Felipe
F
Moscoso J
Rodrigo
R
Quera P
D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D002446:Celiac Disease / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood* / Q000276:immunology; D012680:Sensitivity and Specificity; D011503:Transglutaminases / Q000097:blood* / Q000276:immunology
D001323:Autoantibodies; D015415:Biomarkers; D007070:Immunoglobulin A; D011503:Transglutaminases